Brookline Capital Markets Predicts FBRX FY2026 Earnings

Key Points

• Brookline Capital Markets sharply cut its FY2026 EPS estimate for Forte to ($4.44) from ($2.72) and reduced multi‑year forecasts, signaling the analyst now expects larger near‑term losses than previously modeled.
• Forte priced a $150 million underwritten public offering of 5,709,936 shares at $26.27 (with a 30‑day option for up to 856,490 additional shares), a dilutive deal likely to weigh on the stock short term while raising cash for operations.
• Analyst sentiment is mixed—Weiss Ratings reissued a “sell (e+)” rating while MarketBeat shows a consensus of “Moderate Buy” with a $67 target; the shares traded near $26.27 after Forte missed quarterly EPS estimates (reported -$1.45), and institutional investors own about 77.6% of the stock.

Forte Biosciences, Inc. (NASDAQ:FBRX - Free Report) - Analysts at Brookline Capital Markets decreased their FY2026 earnings estimates for Forte Biosciences in a research note issued on Monday, April 6th. Brookline Capital Markets analyst K. Raja now anticipates that the company will post earnings per share of ($4.44) for the year, down from their prior forecast of ($2.72). The consensus estimate for Forte Biosciences' current full-year earnings is ($12.12) per share. Brookline Capital Markets also issued estimates for Forte Biosciences' FY2027 earnings at ($3.26) EPS, FY2028 earnings at ($2.92) EPS and FY2029 earnings at ($7.49) EPS.

Separately, Weiss Ratings reissued a "sell (e+)" rating on shares of Forte Biosciences in a research report on Friday, March 27th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $67.00.

Forte Biosciences Price Performance

Shares of FBRX opened at $26.27 on Thursday. The firm has a market capitalization of $364.89 million, a PE ratio of -5.51 and a beta of 3.20. The company's 50-day moving average is $28.33 and its 200-day moving average is $22.91. Forte Biosciences has a fifty-two week low of $4.90 and a fifty-two week high of $35.62.

Forte Biosciences (NASDAQ:FBRX - Get Free Report) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($1.45) EPS for the quarter, missing analysts' consensus estimates of ($1.42) by ($0.03).

Hedge Funds Weigh In On Forte Biosciences

A number of hedge funds have recently bought and sold shares of FBRX. Geode Capital Management LLC increased its position in Forte Biosciences by 6.7% during the second quarter. Geode Capital Management LLC now owns 64,110 shares of the company's stock worth $829,000 after acquiring an additional 4,028 shares during the period. Federated Hermes Inc. bought a new position in Forte Biosciences during the second quarter worth about $13,864,000. Orbimed Advisors LLC increased its position in Forte Biosciences by 101.8% during the second quarter. Orbimed Advisors LLC now owns 1,196,955 shares of the company's stock worth $15,477,000 after acquiring an additional 603,867 shares during the period. Cable Car Capital LP increased its position in Forte Biosciences by 127.7% during the second quarter. Cable Car Capital LP now owns 500,000 shares of the company's stock worth $6,465,000 after acquiring an additional 280,396 shares during the period. Finally, Adage Capital Partners GP L.L.C. bought a new position in Forte Biosciences during the second quarter worth about $4,310,000. 77.63% of the stock is owned by institutional investors.

Forte Biosciences News Summary

Here are the key news stories impacting Forte Biosciences this week:

• Neutral Sentiment: Press coverage and analyst roundups that review Forte's outlook and clinical program; background context for investors. Analysts Offer Insights on Healthcare Companies
• Negative Sentiment: Forte priced a sizeable underwritten public offering of 5,709,936 shares at $26.27 per share (company granted underwriters a 30‑day option for up to 856,490 additional shares). All shares are being sold by Forte — the deal will be dilutive and likely puts near‑term downward pressure on the share price, though it does raise cash to fund operations. Forte Biosciences Announces Pricing of $150 Million Public Offering TipRanks: Forte Biosciences Prices $150 Million Public Offering
• Negative Sentiment: Brookline Capital Markets sharply reduced multi‑year EPS forecasts for Forte (FY2026–FY2030), cutting earlier projections across several years — the revisions signal the analyst expects larger near‑term losses than previously modeled and remove upside from earnings/cash‑flow expectations. That weaker analyst outlook amplifies negative sentiment from the equity offering. (See FBRX analyst notes on MarketBeat.) MarketBeat: FBRX Analyst Coverage

Forte Biosciences Company Profile

Forte Biosciences, Inc is a clinical-stage biotechnology company focused on developing innovative treatments to restore skin health by targeting the underlying biology of the skin barrier and microbiome. Headquartered in San Diego, California, Forte leverages proprietary platforms to discover and advance topical live biotherapeutic products and skin barrier therapies aimed at addressing serious dermatological conditions.

The company's lead product candidate, FB-401, is a topical live biotherapeutic formulation designed to rebalance the skin microbiome in patients with atopic dermatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.